Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Bonalfa is a new formulation of Bonalfa ointment, which is currently co-promoted
by the two companies. Tacalcitol, which was initially discovered by Teijin,
is activated vitamin D3.

Indicated for the treatment of keratosis, Tacalcitol is available for sale
in approximately 30 countries worldwide. The two companies aim to generate a
combined total of $7 million in sales per year by 2008.